Amarin Corp. (AMRN) gains 6.3% as major shareholders push for a strategic review to recover value after a dramatic stock drop ...

Amarin Corporation announced the presentation of new in vitro data on eicosapentaenoic acid (EPA) at the American College of Cardiology's Annual Scientific Session & Expo from March 29-31 ...

Q4 2024 Earnings Call Transcript March 12, 2025 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.03, ...

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

Amarin Corp PLC (AMRN) reports strong international growth and strategic advancements despite US market pressures.

Bradley Radoff and Michael Torok, the Managing Director of JEC Capital Partners, who collectively own approximately 15M shares of Amarin ...

DUBLIN and BRIDGEWATER, N.J. - Amarin Corporation plc (NASDAQ:AMRN) announced today that it will present new in vitro data on its cardiovascular drug at the upcoming American College of Cardiology ...

While we appreciate Sarissa Capital Management's ("Sarissa") involvement and commitment to the Company, we believe shareholders would be best served by the Board immediately conducting a strategic ...

Amarin Corporation plc (NASDAQ: AMRN), today announced its intent to effect a ratio change on its American Depositary Shares ("ADS") from ...

Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2024 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur ...